During fall of 2019 and beginning of 2020 GPX Medical participates in PWC’s program to scale up promising European Life Science companies, PWC Scale. GPX Medical was specially selected for the program and will together with PWC experts prepare the company for larger capital investments in 2020 to support the company’s process for CE-Mark and FDA approval for its product NEOLA, Neonatal Lung Analyser, 24 hour monitoring of the lung function of preterm born infants.

About GPX Medical

GPX Medical AB was formed in 2016 as a subsidiary to Gasporox AB (publ) with the aim to develop and commercialize medical applications of the GASMAS technology. The company is owned by Gasporox AB (publ) to 53,3%, by Norsk Elektro Optikk AS to 36,2% and by the team to 10,5%. The company is located in Lund, Sweden. Org. nbr. 559069-9012.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:


GPX Medical AB
Maskinvägen 1
227 30 Lund